Premium
Ethionamide population pharmacokinetics/pharmacodynamics and therapeutic implications in South African adult patients with drug‐resistant tuberculosis
Author(s) -
Mugabo Pierre,
Mulubwa Mwila
Publication year - 2021
Publication title -
british journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.216
H-Index - 146
eISSN - 1365-2125
pISSN - 0306-5251
DOI - 10.1111/bcp.14795
Subject(s) - pharmacokinetics , ethionamide , cmax , medicine , pharmacodynamics , pharmacology , population , volume of distribution , regimen , tuberculosis , elimination rate constant , mycobacterium tuberculosis , ethambutol , environmental health , pathology
Ethionamide is part of the drug‐resistant tuberculosis regimen whose pharmacokinetic (PK) and pharmacodynamic (PD) information is limited. The aim of the study was to describe the PK and simulate doses to assess PD attainment. Methods This was an observational population PK study of patients admitted for drug‐resistant tuberculosis at a hospital in South Africa. Nonlinear mixed‐effects modelling implemented in Monolix 2019R2 was used to estimate population pharmacokinetic parameters. We performed Monte Carlo simulations to assess and optimise the dose regimen. The target C max range was 2.5‐5 μg/mL, which is within the minimum inhibitory concentration (MIC) range. The target AUC 0‐24h was 140.5 μg*h/mL, which corresponds to the PK/PD target ratio AUC 0‐24h /MIC of 56.2. Results A one‐compartment pharmacokinetic model with a lag‐time, first‐order absorption and elimination best described the PK of ethionamide. The lag‐time, absorption rate constant ( ka ), volume of distribution ( V/F ) and clearance ( Cl/F ) were 0.66 hours, 0.434 h −1 , 180 L and 99.5 L/h, respectively, for a typical individual weighing 52.6 kg. Between‐subject variability in lag‐time, ka , V/F and Cl/F were 38%, 92%, 168% and 120%, respectively. Simulation of the recommended doses of 15‐20 mg/kg, 500 mg, 750 mg and 1000 mg for patients in the weight bands <33, 33‐50, 51‐70 and >70 kg resulted in <17% and 3% of the patients achieving the target C max and AUC 0‐24h , respectively. Conclusion There is high variability in ethionamide PK and very few patients attain the desired target exposure at standard or optimised doses. We propose individualised dose regimen optimisation.